Business Context and Reporting Period
This Form 8-K, dated March 31, 2026, reports that Biogen Inc. has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. The transaction involves a tender offer followed by a merger, structured to make Apellis a wholly-owned subsidiary of Biogen.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the acquisition rather than Biogen's operational financial results for the period.
- Upfront Consideration: $41.00 per share of Apellis Common Stock in cash.
- Contingent Value Rights (CVRs): One CVR per share, entitling holders to potential additional cash payments of up to $4.00 per share based on milestones.
- Total Potential Consideration: Up to $45.00 per share ($41.00 cash + $4.00 CVR).
- Termination Fee: $205,000,000 payable by Apellis to Biogen under specific termination scenarios.
- Support Stockholders: Holders of approximately 14% of Apellis shares have agreed to tender their shares and support the merger.
Material Changes and Milestones
The primary material change is the initiation of the acquisition process. The CVR payments are contingent upon the achievement of specific annual net sales milestones for the product SYFOVRE and related products:
- Milestone 1: $2.00 per CVR if annual net sales reach at least $1.5 billion in any calendar year from 2027 through 2030.
- Milestone 2: $2.00 per CVR if annual net sales reach at least $2.0 billion in any calendar year from 2027 through 2031. If Milestone 1 is not met by December 31, 2030, but Milestone 2 is achieved in 2031, the payment increases to $4.00 per CVR.
Guidance, Outlook, and Risks
Management has declared the transaction advisable and fair. The tender offer is expected to remain open for 20 business days. The merger is intended to be effected under Section 251(h) of the Delaware General Corporation Law, meaning no stockholder vote is required if the minimum tender condition is met.
Key Risks and Contingencies:
- Minimum Condition: The offer is subject to receiving tenders for more than 50% of outstanding Apellis shares (plus one share).
- Regulatory Approval: Closing is subject to the expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act and other applicable laws.
- Forward-Looking Statements: The filing warns that drug development and commercialization involve high risks, and there is no assurance that the sales milestones for the CVRs will be achieved.
- Termination: Either party may terminate if the offer is not consummated by September 30, 2026.
Important Facts for Investor Verification
- Verify the final tender offer materials (Schedule TO) for the exact terms and conditions of the offer.
- Monitor the status of antitrust filings and regulatory approvals required for the transaction.
- Assess the likelihood of SYFOVRE achieving the $1.5 billion and $2.0 billion annual net sales thresholds to determine the value of the CVRs.
- Review the full text of the Merger Agreement (Exhibit 2.1) for detailed representations, warranties, and termination rights.
- Note that this filing does not contain Biogen's revenue, profit, or cash flow data for the reporting period.